Article Sidebar
Views PDF: 638
COST-EFFECTIVENESS ASSESSMENT FOR INSULINE GLARGINE AND DETEMIR ON DIABETES MELLITUS TYPE 2 PATIENTS IN VIETNAM
Main Article Content
Abstract
Background and Objectives: Type 2 diabetes mellitus prevalence and mortality is increasing rapidly in recent years. Analog long-acting basal insulin is one of the most important diabetes treatment regimens in Vietnam. This study was conducted to assess the cost-effectiveness of two insulin analogs available in Vietnam: insulin glargine compared to insulin detemir when using for diabetes mellitus type 2 (T2DM) patients in Vietnam, based on published literature. Methods: A decision tree model was developed to assess the associated cost and utility when a patient uses insulin glargine or detemir and their risks of T2DM complications: Myocardial infarction, Stroke, Peripheral diseases and Severe hypoglycemia. Transitional probabilities, costs and utility are adjusted based on the mean %HbA1c reduction and probability of controlling blood glucose (%HbA1c ≤ 7%) for each insulin. Results: Insulin glargine is cost-effective compared to insulin detemir, with lower cost (saving 1,853,848 VND/patient/year) and gaining additional utility (0.008 QALY/patient/year). Conclusions: The study provides the evidence for insulin glargine’s cost-effectiveness when compared to insulin detemir for T2DM treatment in Vietnam.
Article Details
Keywords
diabetes mellitus type 2, cost – effectiveness, insulin glargine, insulin detemir
References
2. Tuan Kiet Pham H, Tuyet Mai Kieu T, Duc Duong T, et al. Direct medical costs of diabetes and its complications in Vietnam: A national health insurance database study. Diabetes Res Clin Pract. 2020;162:108051.doi:10.1016/j.diabres.2020.108051
3. Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):729-736. doi:10.1111/dom.12083
4. Mai T. T. K, Hưng T. T, Đức T. D, et al. Tỉ lệ mắc và chi phí y tế liên quan tới hạ đường huyết ở bệnh nhân đái tháo đường típ 2 tại Việt Nam. Tạp Chí Học Việt Nam. 2020;2(490).
5. Clarke P, Gray A, Holman R. Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22(4):340-349. doi:10.1177/ 027298902400448902
6. Currie CJ, Morgan CLl, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523-1534. doi:10.1185/030079906X115757
7. Permsuwan U, Thavorn K, Dilokthornsakul P, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective. J Med Econ. 2017;20(9):991-999. doi:10.1080/13696998.2017.1347792
8. Guillermin A-L, Samyshkin Y, Wright D, Nguyen T, Villeneuve J. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. J Med Econ. 2011;14(2):207-216. doi:10.3111/ 13696998.2011.561390